Mounjaro Heart Protection: What You Need to Know
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
FDA Expands Mounjaro Approval for Heart Protection (Aug 28, 2026): What the SURPASE Trial Means for Type 2 Diabetes Dr. Kulmeet Kundlas explains the FDA’s August 28, 2026 approval change for Mounjaro (tirzepatide), stating it is now officially approved to reduce the risk of future heart attack and stroke in addition to lowering A1C, supporting weight loss, and improving related metabolic factors. He reviews the SURPASE trial, a large study across 30+ countries with about 13,000 patients, comparing Mounjaro to Trulicity and finding Mounjaro similarly protective and about 1% more effective (13% vs 12%) despite participants already maximizing blood pressure, cholesterol, lifestyle, and standard therapies. He discusses inflammation as a key mechanism via GLP-1 and GIP receptor activity, notes common GI side effects and contraindication with medullary thyroid carcinoma, and emphasizes benefits depend on continued diet, exercise, resistance training, and high-protein intake.